Zobrazeno 1 - 10
of 109
pro vyhledávání: '"Sander, Bins"'
Autor:
Wesley S. van de Geer, Ron H.J. Mathijssen, Job van Riet, Neeltje Steeghs, Mariette Labots, Carla van Herpen, Lot A. Devriese, Vivianne C.G. Tjan-Heijnen, Emile E. Voest, Stefan Sleijfer, John W.M. Martens, Edwin Cuppen, Harmen J.G. van de Werken, Sander Bins
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 159, Iss , Pp 114210- (2023)
Drug resistance is a perpetual problem in cancer therapy with many underlying mechanisms. Alterations in drug transport over the cancer cell membrane can severely alter intratumoral drug exposure, contributing to resistance. Here, we present the soma
Externí odkaz:
https://doaj.org/article/dfde034a6bb040089d45cdf4f8ef6c58
Autor:
Mirjam de With, Leni van Doorn, Demi C. Maasland, Tessa A.M. Mulder, Esther Oomen-de Hoop, Bianca Mostert, Marjolein Y.V. Homs, Samira El Bouazzaoui, Ron H.J. Mathijssen, Ron H.N. van Schaik, Sander Bins
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 159, Iss , Pp 114232- (2023)
Aim of the study: Occurrence of hand-foot syndrome (HFS) during capecitabine treatment often results in treatment interruptions (26 %) or treatment discontinuation (17 %), and can severely decrease quality of life. In this study, we investigated whet
Externí odkaz:
https://doaj.org/article/22d712ca5f2d4b6f9d5ea8fc0cd5da1f
Autor:
Edwin A. Basak, Karlijn de Joode, Tom J.J. Uyl, Ronald van der Wal, Marco W.J. Schreurs, Sjoerd A.A. van den Berg, Esther Oomen-de Hoop, Cor H. van der Leest, Layal Chaker, Richard A. Feelders, Astrid A.M. van der Veldt, Arjen Joosse, Stijn L.W. Koolen, Joachim G.J.V. Aerts, Ron H.J. Mathijssen, Sander Bins
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 156, Iss , Pp 113839- (2022)
Introduction: Immune checkpoint inhibitor (ICI) associated diabetes is a harmful adverse event (AE) in patients with cancer following anti-programmed (cell) death protein-1 (PD-1) treatment. There are no available biomarkers able to predict this AE.
Externí odkaz:
https://doaj.org/article/6bde66b85d864af29f569f89ed5b8a51
Autor:
Ruben A. G. van Eerden, Leni van Doorn, Femke M. de Man, Niels Heersche, Michail Doukas, Thierry P. P. van den Bosch, Esther Oomen-de Hoop, Peter de Bruijn, Sander Bins, Eman Ibrahim, Suzan Nikkessen, Lena E. Friberg, Stijn L. W. Koolen, Manon C. W. Spaander, Ron H. J. Mathijssen
Publikováno v:
Frontiers in Pharmacology, Vol 12 (2021)
Background: Data from previous work suggests that there is no correlation between systemic (plasma) paclitaxel exposure and efficacy in patients treated for esophageal cancer. In this trial, we investigated ATP-binding cassette efflux transporter exp
Externí odkaz:
https://doaj.org/article/2da8bb17075a4bb7a21f579be94bb87f
Autor:
Tessa A. M. Mulder, Ruben A. G. van Eerden, Mirjam de With, Laure Elens, Dennis A. Hesselink, Maja Matic, Sander Bins, Ron H. J. Mathijssen, Ron H. N. van Schaik
Publikováno v:
Frontiers in Genetics, Vol 12 (2021)
Cytochrome P450 3A4 (CYP3A4) is the most important drug metabolizing enzyme in the liver, responsible for the oxidative metabolism of ∼50% of clinically prescribed drugs. Therefore, genetic variation in CYP3A4 could potentially affect the pharmacok
Externí odkaz:
https://doaj.org/article/80b85a597c65408aa28ded486cfab7e7
Autor:
Daan P. Hurkmans, Edwin A. Basak, Tanja van Dijk, Darlene Mercieca, Marco W. J. Schreurs, Annemarie J. M. Wijkhuijs, Sander Bins, Esther Oomen-de Hoop, Reno Debets, Markus Joerger, Arlette Odink, Astrid A. M. van der Veldt, Cor H. van der Leest, Joachim G. J. V. Aerts, Ron H. J. Mathijssen, Stijn L. W. Koolen
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-11 (2019)
Abstract Background Nivolumab is administered in a weight-based or fixed-flat dosing regimen. For patients with non-small cell lung cancer (NSCLC), a potential exposure-response relationship has recently been reported and may argue against the curren
Externí odkaz:
https://doaj.org/article/f8d983aed7774b85a3a382836c2bce1a
Autor:
Andre Kunert, Edwin A. Basak, Daan P. Hurkmans, Hayri E. Balcioglu, Yarne Klaver, Mandy van Brakel, Astrid A. M. Oostvogels, Cor H. J. Lamers, Sander Bins, Stijn L. W. Koolen, Astrid A. M. van der Veldt, Stefan Sleijfer, Ron H. J. Mathijssen, Joachim G. J. V. Aerts, Reno Debets
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-13 (2019)
Abstract Background Checkpoint inhibitors have become standard care of treatment for non-small cell lung cancer (NSCLC), yet only a limited fraction of patients experiences durable clinical benefit, highlighting the need for markers to stratify patie
Externí odkaz:
https://doaj.org/article/85ac7d6b829b414e9203975733252de9
Autor:
Niels A. D. Guchelaar, Bo J. Noordman, Stijn L. W. Koolen, Bianca Mostert, Eva V. E. Madsen, Jacobus W. A. Burger, Alexandra R. M. Brandt-Kerkhof, Geert-Jan Creemers, Ignace H. J. T. de Hingh, Misha Luyer, Sander Bins, Esther van Meerten, Sjoerd M. Lagarde, Cornelis Verhoef, Bas P. L. Wijnhoven, Ron. H. J. Mathijssen
Publikováno v:
Drugs, 83(2), 159-180. Adis
Malignancies of the peritoneal cavity are associated with a dismal prognosis. Systemic chemotherapy is the gold standard for patients with unresectable peritoneal disease, but its intraperitoneal effect is hampered by the peritoneal-plasma barrier. I
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3cebd8e4086bfc35d390fbbafcf04f1e
https://doi.org/10.1007/s40265-022-01828-7
https://doi.org/10.1007/s40265-022-01828-7
Autor:
Reno Debets, Edwin A. Basak, Daan P. Hurkmans, Sander Bins, Stijn L. W. Koolen, Astrid A. M. van der Veldt, Stefan Sleijfer, Ron H. J. Mathijssen, Joachim G. J. V. Aerts, Ron H. N. van Schaik, Cor H. van der Leest, Nina Schepers, Esther Oomen-De Hoop, Samira El Bouazzaoui
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)
Background A minority of patients with advanced non-small-cell lung cancer (NSCLC) benefit from treatment with immune checkpoint inhibitors (ICIs). Ineffective effector function of activated T and NK cells may lead to reduced tumor cell death, even w
Externí odkaz:
https://doaj.org/article/81ec1929bfab4cc5a86e10e660b32778
Autor:
Edwin A. Basak, Niels S. Vermeer, Karlijn de Joode, Daan P. Hurkmans, Dorian E.M. Velthuis, Esther Oomen-de Hoop, Marco W.J. Schreurs, Sander Bins, Stijn L.W. Koolen, Reno Debets, Astrid A.M. van der Veldt, Joachim G.J.V. Aerts, Arjen Joosse, Ron H.J. Mathijssen
Publikováno v:
European Journal of Cancer, 174, 113-120. Elsevier Ltd.
AIM: With increasing use of immune checkpoint inhibitors (ICIs) more patients will develop severe and potentially life-threatening immune-related adverse events (irAEs). So far, predictive models for the occurrence of grade ≥3 irAEs are lacking. Th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::412001a708378502415a952c5d8415ce
https://doi.org/10.1016/j.ejca.2022.07.015
https://doi.org/10.1016/j.ejca.2022.07.015